F.D.A. Stays Neutral on the Need for a Moderna Booster
The advisory committee is also likely to consider whether Moderna’s protection against severe disease and hospitalization may eventually weaken. Booster proponents argue that Moderna’s potency is declining much like Pfizer’s, which is based on the same technology, only more slowly because its initial dosage is significantly stronger than Pfizer’s and the interval between the first…